News Releases

News Releases
Events
Presentations

Year

October 10, 2019

DURHAM, NC – October 10, 2019 – In support of World Arthritis Day, which is celebrated every October 12 to raise awareness of arthritis, Bioventus , a global leader in orthobiologics, has launched a disease and product information website called OAKneePainRelief.com which combines information on

October 8, 2019

National Institute for Health and Clinical Excellence Maintains Previous Recommendation for EXOGEN® Ultrasound Bone Healing System

HOOFDDORP, THE NETHERLANDS – October 8, 2019 – Bioventus , a global leader in orthobiologic solutions, has received notice from the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) that it has updated its guidance (MTG12) regarding the use of the EXOGEN Ultrasound Bone

September 9, 2019

Bioventus Agrees to Nationwide Contract with UnitedHealthcare® Commercial Plans, Members Have Access to DUROLANE® and GELSYN-3®for Knee Osteoarthritis

DURHAM, NC – September 9, 2019 – Bioventus , a global leader in orthobiologic solutions, has agreed to a nationwide contract with UnitedHealthcare Employer & Individual commercial plans. Beginning October 1, 2019, UnitedHealthcare commercial plan members will have access to both DUROLANE and

August 13, 2019

Bioventus Launches DUROLANE® SJ (1mL) in Australia and New Zealand; Receives Expanded Indications for DUROLANE (3mL)

HOOFDDORP, THE NETHERLANDS – August 13, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE SJ (1mL) , and has received expanded indications for DUROLANE (3mL), its single-injection joint-fluid osteoarthritis (OA) treatment, in Australia and New Zealand.

June 6, 2019

Bioventus to Co-Develop Next Generation Placental Tissue Product for Knee Osteoarthritis with MTF Biologics

DURHAM– June 6, 2019 – Bioventus , a global leader in orthobiologic solutions, has entered into a development collaboration agreemen t with MTF Biologics , the world’s largest tissue bank, to co-develop a next generation placental tissue product for the treatment of painful musculoskeletal

March 27, 2019

Bioventus Launches OSTEOAMP SELECT Fibers

DURHAM, NC – March 27, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEO AMP SELECT Fibers , an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons.

January 29, 2019

Bioventus Launches DUROLANE in Malaysia

HOOFDDORP, THE NETHERLANDS – January 29, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment, in Malaysia and has selected Athrotech as its exclusive distribution partner for the market.

January 15, 2019

Bioventus Launches OSTEOMATRIX+® Biphasic Bone Graft

DURHAM, NC – January 15, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEOMATRIX+, its next generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications. OSTEOMATRIX+ is a moldable bone graft substitute consisting of

October 25, 2018

Susan M. Stalnecker Named to Bioventus Board of Managers

DURHAM, NC – October 25, 2018 – Bioventus , a global leader in orthobiologic solutions, today announced the appointment of Susan M. Stalnecker, former Vice President and Treasurer, E.I. du Pont de Nemours and Company, to the company’s Board of Managers, replacing Michael Minogue.

October 2, 2018

Bioventus Receives ANVISA Approval to Market DUROLANE in Brazil and Selects Pfizer as Exclusive Distribution Partner

HOOFDDORP, THE NETHERLANDS – October 2, 2018 – Bioventus , a global leader in orthobiologic solutions, has received approval from Agência Nacional de Vigilância Sanitária (ANVISA) to market DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment, in Brazil.

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Current page 12
Page 13
Next page
Last page

Displaying 111 - 120 of 126